Adicet Bio, Inc.
ACET US
ACET USAdicet Bio, Inc.
United States Composite1.68
- Business
- Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Company News
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Why Adicet Bio (ACET) Stock Might be a Great Pick
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adicet Bio (ACET) Receives a New Rating from Truist Financial
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
Buy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy Developments
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)